InvestorsHub Logo
Followers 8
Posts 1224
Boards Moderated 0
Alias Born 07/16/2006

Re: sons post# 261

Wednesday, 02/13/2008 9:22:55 PM

Wednesday, February 13, 2008 9:22:55 PM

Post# of 4681
Also noteworthy is Dr. Kensey's prior company, again local to me which trades at $29.00 on the NASDAQ
http://finance.google.com/finance?client=ob&q=KNSY

Innovative Technology For Medicine

Kensey Nash Corporation is a medical device company known for providing innovative product development and advanced technology for a wide range of medical procedures. The Company has expanded well beyond its beginnings in vascular puncture closure and today, through its biomaterials and endovascular business units provides an extensive range of products into multiple medical markets.

As the inventor of the Angio-Seal™ Vascular Closure Device, now manufactured, marketed and sold by St. Jude Medical Inc., Kensey Nash Corporation pioneered the concept of arterial closure -- establishing itself as an innovative leader in cardiovascular technology. That innovative ability enabled the Company to expand its biomaterials technology and it now designs, develops and manufactures biomaterials-based products which are commercially available in the fields of orthopaedics (including sports medicine and spine), cardiology, drug delivery, oral care, general surgery, trauma and wound care. These biomaterial based products include synthetic polymers, collagen, polysaccharides and ceramics which are turned into novel products in the areas of soft and hard tissue fixation, soft and hard tissue regeneration and biologic drug carriers which are manufactured for and distributed by Fortune 100 companies and emerging new technology companies alike.

Kensey Nash’s endovascular business currently manufactures, markets and sells products that address the thrombus management and vascular occlusive markets. The QuickCat™ Extraction Catheter removes soft, fresh thrombus. The ThromCat™ Mechanical Thrombectomy Catheter System utilizes HeliFlex™ technology to flush, macerate and extract thrombus while the Safe-Cross™ Radio Frequency Total Occlusion Crossing System utilizes guide wire technology to cross and recanalize Chronic Total Occlusions (CTOs).

http://www.kenseynash.com/

No joke here boys. Fonz is a stud. Rheologics is for real as is the new company. Everyone understand what we are dealing with?

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.